

B

Enriched Pathway in neonate islets

| GO Biological Function | Count | p value |
|--|-------|----------|
| cell adhesion | 114 | 1.40E-25 |
| vasculature matrix organization | 57 | 3.80E-15 |
| extracellular matrix organization | 31 | 5.40E-12 |
| regulation of cell proliferation | 84 | 5.70E-12 |
| cell motion | 65 | 8.50E-12 |
| regulation of cell migration | 26 | 2.50E-09 |
| response to hypoxia | 18 | 1.30E-06 |
| regulation of Wnt receptor signaling pathway | 9 | 5.00E-03 |

C

Enriched Pathway in adult islets

| GO Biological Function | Count | p value |
|--|-------|----------|
| vesicle-mediated transport | 57 | 1.60E-08 |
| monosaccharide metabolic process | 26 | 3.90E-05 |
| oxidation reduction | 60 | 1.60E-04 |
| secretion | 27 | 1.60E-04 |
| cation transport | 49 | 1.70E-04 |
| generation of precursor metabolites and energy | 26 | 4.10E-03 |
| ATP biosynthetic process | 10 | 3.30E-02 |
| electron transport chain | 8 | 4.10E-01 |







Figure S1




Figure S2




Figure S3









Figure S4




A

| GO Biological Function | Count | p-value |
|---------------------------------|-------|----------|
| response to organic substance | 204 | 2.00E-17 |
| M phase of mitotic cell cycle | 75 | 2.60E-10 |
| nuclear division | 74 | 2.80E-10 |
| mitosis | 74 | 2.80E-10 |
| intracellular signaling cascade | 283 | 5.50E-10 |
| response to hormone stimulus | 106 | 7.80E-10 |
| cell cycle | 190 | 7.90E-10 |
| organelle fission | 75 | 8.20E-10 |
| regulation of apoptosis | 195 | 1.10E-09 |
| cell division | 89 | 2.00E-09 |



B



C






Figure S6

human islets



iβeta



Mock




Figure S7

Table S2

| ETC/OxPhos/TCA GeneSymbol | Log2 Fold change | |
|------------------------------|------------------|-----------------|
| | vs iPSC EGFP | vs iPSC ERRg |
| ACO2 | 1.59873 | 2.80003 |
| ALDH5A1 | 1.49639 | 3.37664 |
| ATP5A1 | Not Sig | 0.277102 |
| ATP5B | Not Sig | 0.846419 |
| ATP5E | 0.731179 | 1.25099 |
| ATP5G1 | 0.254222 | 1.05967 |
| ATP6V0E2 | Not Sig | 0.900001 |
| ATP6V1E1 | 0.626112 | 1.30561 |
| ATP6V1F | 0.45153 | 1.02396 |
| CYC1 | 0.603286 | 0.896287 |
| DLAT | 0.334244 | 0.961947 |
| DLD | 0.441694 | 0.921321 |
| DLST | Not Sig | 0.780315 |
| ENOX1 | 2.7392 | 4.74469 |
| ERO1LB | 0.672097 | 1.29379 |
| FDX1L | Not Sig | 0.434021 |
| FDXR | Not Sig | 3.67598 |
| FH | 0.241744 | 0.74715 |
| FXN | -0.948575 | Not Sig |
| GLRX | 0.501042 | 1.11671 |
| IDH3B | Not Sig | 1.14196 |
| IDH3G | 0.950187 | 1.75898 |
| MDH1 | -0.255856 | 1.10709 |
| NDUFA10 | 0.499061 | 0.948454 |
| NDUFA11 | Not Sig | 0.564872 |
| NDUFA12 | 0.25208 | 0.704452 |
| NDUFA2 | Not Sig | 0.914633 |
| NDUFA3 | -0.220469 | 0.553712 |
| NDUFA5 | Not Sig | 1.07434 |
| NDUFA6 | 0.379207 | 0.874344 |
| NDUFA7 | Not Sig | 0.75212 |
| NDUFA8 | Not Sig | 0.413066 |
| NDUFA9 | 0.755382 | 1.65441 |
| NDUFAB1 | -0.381263 | Not Sig |
| NDUFB2 | 0.597611 | 1.033 |
| NDUFB5 | 0.273809 | 0.774613 |
| NDUFB6 | -0.311921 | 0.189206 |
| NDUFB8 | Not Sig | 0.544258 |
| NDUFB9 | 0.263353 | 0.994521 |
| NDUFS1 | 0.379948 | 1.35876 |
| NDUFS2 | Not Sig | 0.50899 |
| NDUFS3 | Not Sig | 0.671524 |
| NDUFS5 | -0.917236 | -0.466569 |
| NDUFV1 | 0.551033 | 1.44145 |
| PDHB | -0.842791 | 0.669281 |
| SDHA | 0.790141 | 1.60913 |
| SDHB | 0.407439 | 1.09377 |
| SDHC | -0.273585 | 0.383452 |
| SLC1A3 | -0.511466 | 2.37408 |
| SLC25A12 | Not Sig | 0.839587 |
| SLC25A13 | Not Sig | 0.566767 |
| SNCA | Not Sig | 1.43413 |
| TMX4 | 2.1645 | 3.28654 |
| TXNRD3 | Not Sig | 1.52149 |
| UQCRC10 | 0.592409 | 1.2018 |
| UQCRCB | Not Sig | 0.632791 |
| UQCRC2 | 0.34232 | 0.837592 |
| UQCRCFS1 | 0.309875 | 0.760593 |
| Cell Cycle GeneSymbol | vs iPSC EGFP | vs iPSC ERRg |
| CDC14A | -0.380578 | -1.03937 |
| CDC14B | -0.69238 | -1.25311 |
| CREBBP | 0 | -0.833229 |
| DBF4 | -1.1856 | -1.47334 |
| EP300 | -0.688392 | -1.09124 |
| E2F1 | -1.12537 | -1.97869 |
| E2F3 | -1.09357 | -1.52456 |
| E2F4 | -0.265279 | -0.470933 |
| MAD2L1 | -2.44662 | -3.14233 |
| RAD21 | -1.36874 | -2.20653 |
| SMAD3 | 2.08416 | 1.84569 |
| SMAD4 | -0.553343 | -0.94641 |
| TTK | -2.55557 | -3.36766 |
| ANAPC2 | 1.05548 | 0.704531 |
| BUB1 | -3.38933 | -3.70847 |
| BUB1B | -3.69111 | -4.09542 |
| ABL1 | -0.813672 | -1.13291 |
| CDK1 | -2.26848 | -2.6219 |
| CDC20 | -2.48852 | -2.90934 |
| CDC25B | 0.751421 | 0.343281 |
| CDC26 | -0.348854 | -1.21828 |
| CDC27 | 0.376144 | 0 |
| CCNA2 | -2.40664 | -3.15337 |
| CCNB1 | -2.51698 | -2.88801 |
| CCNB2 | -2.98725 | -3.35154 |
| CCND2 | -0.847802 | -0.899491 |
| CDKN1B | 0.42953 | -0.0322305 |
| CDKN2D | 1.98428 | 1.68098 |
| HDAC1 | 0 | -0.62393 |
| HDAC2 | -1.24824 | -1.43757 |
| MCM2 | -2.56831 | -3.01465 |
| MCM3 | -1.91484 | -2.34638 |
| MCM4 | -1.68462 | -2.42024 |

| | | |
|-------|------------|-----------|
| MCM5 | -3.09236 | -3.60412 |
| MCM7 | -1.99523 | -2.8826 |
| PTTG1 | -2.75808 | -3.34462 |
| PLK1 | -2.78904 | -3.41241 |
| PCNA | -1.12241 | -1.77944 |
| CHEK2 | -2.99836 | -3.54351 |
| RB1 | 0.839276 | 0.601377 |
| RBL1 | -0.402046 | -0.853579 |
| STAG1 | 0.269041 | -0.287144 |
| STAG2 | -1.47451 | -1.94558 |
| SMC1A | -0.759328 | -1.12585 |
| SMC3 | -1.5107 | -1.83194 |
| TFDP1 | 0.237269 | -0.327076 |
| YWHAB | -0.166558 | -0.424803 |
| YWHAG | -0.0469328 | -0.429083 |
| YWHAQ | -0.599707 | -0.802293 |
| YWHAZ | 0.370218 | -0.281107 |

| Beta Cell | vs iPSC | vs iPSC |
|------------|----------|-----------|
| GeneSymbol | EGFP | ERRg |
| INS | infinity | infinity |
| PDX1 | infinity | infinity |
| IAPP | -1.0251 | 1.54488 |
| FOXA2 | 7.08098 | 6.07311 |
| GATA4 | 7.10581 | 8.19732 |
| GATA6 | 9.68187 | 9.71362 |
| MAF | 4.1695 | 5.41346 |
| MAFA | No Test | No Test |
| MAFB | 2.32924 | 1.69467 |
| NEUROD1 | 5.23953 | 3.96233 |
| PAX4 | 1.00481 | 0.0836628 |
| PAX6 | 0.891676 | 0.309519 |
| NKX2-2 | 3.73834 | 3.46179 |
| NKX6-1 | 2.55188 | 2.40718 |
| NKX6-2 | 7.04707 | 5.21865 |
| NANOG | -9.38333 | -10.2497 |

Table S3

| IIDP Donor ID | Internal ID | Sex | Age (years) | Race | BMI | Cause of Death | Experiment | Corresponding Figures |
|---------------|-------------|--------|-------------|---------------------------|-------|------------------------|--|---------------------------|
| | 785 #1 | Male | 50 | White | 28.99 | Cerebrovascular/stroke | cDNA library for qPCR | Data not shown |
| | 790 #2 | Female | 24 | Hispanic/Latino | 34.9 | Head trauma | cDNA library for qPCR | Data not shown |
| | 794 #3 | Female | 41 | White | 35.5 | Head trauma | cDNA library for qPCR | Data not shown |
| | 807 #4 | Female | 26 | White | 46.6 | Head trauma | cDNA library for qPCR | Data not shown |
| | 821 #5 | Male | 27 | Asian | 22.1 | Anoxia | cDNA library for qPCR | Data not shown |
| | 824 #6 | Female | 47 | White | 20.6 | Cerebrovascular/stroke | cDNA library for qPCR | Data not shown |
| | 882 #7 | Male | 50 | Hispanic/Latino | 25.7 | Cerebrovascular/stroke | cDNA library for qPCR | Data not shown |
| | 915 #8 | Male | 31 | White | 31.7 | Head trauma | cDNA library for qPCR | Data not shown |
| | 937 #9 | Male | 52 | White | 34.3 | Anoxia | glucose stimulated c-peptide secretion | Data not shown |
| | 975 #10 | Male | 54 | Black or African American | 23.3 | Cerebrovascular/stroke | glucose stimulated c-peptide secretion | Figure 4E |
| | 979 #11 | Male | 53 | White | 27.2 | Cerebrovascular/stroke | cDNA library for qPCR | Figure S5J |
| | 985 #12 | Male | 40 | White | 38.91 | No info | cDNA library for qPCR | Data not shown |
| | 1042 #13 | Male | 37 | White | 26.3 | Anoxia | islets transplantation in NOD-SCID | Figure 6B, 6C, Figure S6B |
| | 1050 #14 | Male | 36 | White | 26 | Anoxia | islets transplantation in NOD-SCID | Figure 6B, 6C, Figure S6B |
| | 1059 #15 | Male | 32 | White | 23.1 | Anoxia | cDNA library for qPCR | Figure 5A,5B,5C |
| | 1060 #16 | Female | 47 | White | 25 | Cerebrovascular/stroke | cDNA library for qPCR | Figure 5A,5B,5C |
| | 1061 #17 | Male | 33 | Hispanic/Latino | 31.5 | Head trauma | cDNA library for qPCR | Figure 5A,5B,5C |
| | 1082 #18 | Female | 49 | White | 30.3 | Cerebrovascular/stroke | glucose stimulated c-peptide secretion | Figure 4E |
| | 1089 #19 | Female | 51 | Hispanic/Latino | 25.4 | Cerebrovascular/stroke | EM study | Data not shown |

Table S4

| qPCR primers | | | | |
|--------------------------------|----------------------|-----------------------------|-----------------------------------|-------------------------------|
| NCBI or Primer bank ID | Genes | Species | Primers (Fw) | Primers (Rv) |
| NM_001243792.1 | ERRy | mouse | gcaaggcattcttcaagagg | ggctgggcagctgactcta |
| NM_001136069.2 | Ldha | mouse | ccgttacctgatggagaga | gtaggcactgtccaccacct |
| NM_008618.3 | Mdh1 | mouse | gaagccctgaaagacgacag | tcgacacgaacctccctct |
| NM_009943.2 | Cox6a2 | mouse | ctctgcactgggtgaaggag | gaaggaccagacaagaagtc |
| L09192.1 | Pcx | mouse | cctctcagagcgcagcagact | atagggaagccgaaggtgtt |
| NM_010886.2 | Ndufa4 | mouse | ctgcgttaggttaggcctgt | catggctctgggtgttctt |
| NM_153064.4 | Ndufs2 | mouse | gatccgagtgctcttggag | atgtcatccagaagcccaag |
| NM_009722.3 | Atp2a2 | mouse | ctgtggagacccttgggtgt | cagagcacagatggggcta |
| NM_011596.5 | Atp6v0a2 | mouse | cacgaagaccttctcaagc | ccagctctcataggtcaca |
| NM_001185083.1 | Ins2 | mouse | tttgaagcagcacctttg | tctacaatgccagctctctg |
| NM_001039710.1 | Coq10b | mouse | ccccgtctggagagataca | tagcagctcagagtgacaga |
| NM_023179.3 | Atp6v1g2 | mouse | ctggaagcctcagtgctctc | tcacagtggtgaacaaagc |
| NM_001103157.1 | Steap2 | mouse | gcagagcaggagaaatggac | ctttcttcgggatgccata |
| NM_001177752.1 | Pfkfb3 | mouse | ccgacagaactggagaggag | agcggagacacgagacagat |
| NM_000207.2 | Insulin | human | agccttggtaaccaaccacc | gctggtagggagcagatg |
| NM_206594.2 | ERRy | human | gtaaacactgtcgagtttga | cgaacacgtggaatcaatgtg |
| NM_024865.2 | Nanog | human | ttccttctccatggatctg | tctgctgaggctgaggtat |
| NM_001165923.2 | HNF1β | human | tcacagatacagcagcatcagt | gggcctaccaggctgtga |
| NM_022454.3 | Sox17 | human | cctgggttttgggttctgt | gaggaagctgttttgggaca |
| NM_000209.3 | Pdx1 | human | ggatgaagtctacaaagctcacgc | ccagatcttgatgtctctggtc |
| NM_201589 | Mafa | human | cttcagcaaggaggaggtatc | ctctgtttctctgttacaggtcc |
| NM_006168.2 | Nkx6.1 | human | attcgttgggatgacagag | tcaacagctcgtgattttc |
| NM_002500.4 | NeuroD1 | human | gttctcagagcaggagcac | cttggcctttgatgctcat |
| NM_000162.3 | Gck | human | gctggaatcaattcccaga | ctccccacacagatgagtt |
| NM_014232.2 | Vamp2 | human | tccccagctggtatgtaag | ccacacacacactgtagcc |
| NM_002054.4 | Gcg | human | aggcagaccctcagtgga | aacaatggcgacctctctg |
| NM_001048.3 | Sst | human | gtactcttggcagagctgctg | cagaagaattcttgcagccag |
| 260099724c1 | Ldha | human | atggcaactcaaaggatcagc | ccaaccacaactgtatct |
| NM_001199111 | Mdh1 | human | cccgaataaggaggaggt | ccgtaacctctttggaaaa |
| 34147589c1 | Ndufa4 | human | atgatcggcttaactcctg | tccgggtgttcttctgtcc |
| NM_000920.3 | Pcx | human | ccagaggcaggtcttctttg | gggtgaggtcaccacagctc |
| NM_145230.3 | Atp6v0e2 | human | agtatcctgttcgctcct | ctctcatcccagctctggtc |
| 25121968c1 | Kcnj8 | human | aacctggcgcaataagaacatc | ccacatgatagcgaagagcag |
| 20336240c1 | Pcsk1 | human | accccgagctgttgagta | gggtctctagcggtttcaca |
| 206725425c1 | Kcnk1 | human | cctgggaaggctacaatcaa | ccagaactaccaataggcaa |
| 197245365c1 | Kcnk3 | human | ctacgagcactggaccttct | cgtaaggatgtagcgaagctga |
| NM_001002.3 | U36B4 (RPLP0) | human/mouse/rat | gtgctgatgggcaagaac | aggtcctcttggtagaac |
| NM_203336 | ERRy | Rat | cagctgttctccttcatca | tctgggactctctacgatg |
| ChIP primers | | | | |
| Reference | Genes | Species | Primers (Fw) | Primers (Rv) |
| Dofour et al, Cell Metab, 2007 | Mdh1 | mouse | cgccagaggtcgccggaagaactcac | ccaggagccccacatccattattgc |
| Dofour et al, Cell Metab, 2007 | Atp2a2 | mouse | gtatgttttagacaaggtccaactgtg | caaggttaattttccaataaaagagg |
| Active Motif | EF1a | mouse | CHIP-IT Control Kit-Mouse No53011 | |
| Genotyping Primers | | | | |
| Reference | Genes | Animal model | Primers (Fw) | Primers (Rv) |
| - | ERRy | ERRy flox/flox | gttttaaagcccttgggtatctgc | ctgcaaccttggactccagaac |
| - | Cre | Cre positive | gcattaccggtcgatgcaacgagtgatgag | gagtgaaacgaacctgtcgaatcagtgcg |
| - | FABP3 | internal control for Cre | tggacagactggacctctgc | tagactttgccacatcacag |
| - | Insulin GFP promoter | MIP-GFP | aagttcatctgcaccaccg | tccttgaagaagatgggtgc |
| - | Insulin GFP promoter | internal control for MIPGFP | ctaggccacagaattgaaagatct | gtaggtggaaattctagcatcatcc |

Table S5

| Material | Dilution | Company | Catalog Number | STOCK solution | Final Concentration | Expected effect |
|---|---|---|---|---|--|--|
| rh/m/r Activin A | 0.1% BSA PBS | R&D systems | 338-AC | 100ug/ml | 100ng/ml | TGFβ super family |
| rhWnt3a | 0.1% BSA PBS | R&D systems | 5036-WN | 25ug/ml | 25ng/ml | Wnt signaling |
| CHIR99021 | DMSO | Axon | 1386 | 3mM | 3uM | GSK3β inhibitor |
| Wortmannin | DMSO | Invivo Gen | 10C22-MM | 100uM | 100nM | PI3K inhibitor |
| Retinoic acid | DMSO | SIGMA | R2625-1G | 2uM | 2mM | Retinoic acid signal |
| SB431542 | DMSO | SIGMA | S4317-5MG | 10uM | 10mM | TGFβRI inhibitor |
| Dorsomorphin | DMSO | Bio vision | 1686-5 | 1mM | 1uM | BMP type I R inhibitor |
| rhFGF10 | 0.1% BSA PBS | R&D systems | 345-FG | 50ug/ml | 50ng/ml | FGF10 signaling |
| rhFGF7/KGF | 0.1% BSA PBS | R&D systems | 251-KG/CF | 25ug/ml | 25-50ng/ml | FGF7 signaling |
| KAAD-cyclopamine | DMSO | STEMGENT | 04-0028 | 0.25mM | 0.25uM | Hedgehog signaling inhibitor |
| rhNoggin | 0.1% BSA PBS | R&D systems | 6057-NG | 50ug/ml | 50ng/ml | BMP4 inhibitor |
| rhFGF2 | 0.1% BSA PBS | Peprotech | 100-18B | 10ug/ml | 10ng/ml | FGF2 signaling |
| rhBMP4 | 0.1% BSA PBS | R&D systems | 314-BP | 10ug/ml | 10ng/ml | BMP4 signaling |
| Forskolin | DMSO | SIGMA | F6886-25MG | 10mM | 10uM | Adenylate cyclase activator |
| Dexametazon | DMSO | SIGMA | D4902-100MG | 10mM | 10uM | Glucocorticoid receptor signaling |
| TGF-β RI kinase inhibitor II (Alk5i II) | DMSO | Calbiochem or Enzo | 616452 or ALX-270-445 | 10mM | 10uM | TGFβRI inhibitor |
| Nicotinamide | H2O or PBS | SIGMA | 72340-100G | 1M | 10mM | Vitamin B3 |
| Exendin4 | H2O or PBS | SIGMA | E7144 | 1mg/ml | 1ug/ml | GLP1 analog |
| human GLP1 | 0.1% BSA PBS | Peprotech | 130-08 | 1mg/ml | 1ug/ml | GLP1 signaling/cAMP activation |
| human IGF2 | 0.1% BSA PBS | Prospec | cyt-265-b | 10ug/ml | 10ng/ml | IGF2 signaling |
| B27 Supplement | - | GIBCO | 17504-044 | - | 1% | Growth supplement |
| N2 Supplement | - | GIBCO | 17502-048 | - | 1% | Growth supplement |
| Insulin-Transferrin-Selenium | - | GIBCO | 41400-045 | - | 1% | Growth supplement |
| Reserpine | DMSO | TOCRIS | 2742 | 0.63mM | 0.63uM | VMAT inhibitor |
| Tetrazepam (TBZ) | DMSO | TOCRIS | 2175 | 1.25mM | 1.25uM | VMAT inhibitor |
| dBu-cAMP | DMSO | ENZO | BML-CN125-0100 | 0.6mM | 0.6uM | cAMP activation |
| R428 | DMSO | Selleckchem | S2841 | 2mM | 2uM | Axl inhibitor |
| 3,3',5-Triiodo-L-thyronine sodium salt (T3) | DMSO | SIGMA | T6397-100MG | 1mM | 1uM | Thyroid hormone |
| Stemolecule™ LDN-193189 | DMSO | Stemgent | 04-0074-10 | 100uM | 100nM | TGFβ/Smad inhibitor |
| SANT-1 | DMSO | SIGMA | S4572-5MG | 0.25mM | 0.25uM | Hedgehog/Smoothed antagonist |
| N-acetyl cysteine | H2O | SIGMA | A9165 | 100mM | 1mM | Anti oxidants |
| Gamma Secretase inhibitor XX (GSiXX) | DMSO | Millipore | 565789 | 100uM | 100nM | Notch inhibitor |
| Betacellulin (BTC) | 0.1% BSA PBS | Millipore EMD | 200496-10UG | 20ug/ml | 20ng/ml | EGFR ligand |
| Heparin | H2O | SIGMA | H3149-10KU | 10mg/ml | 10ug/ml | Enhance Growth hormone binding |
| Days for differentiation | 0 day | 1~2 day | 3~4 day | 5~11 day | 12~21 day | 21 day~ |
| Virus or Reagents | Infection Human Insulin Reporter Lenti Virus (pGreenZeo System) 800g 1 hour spin fection Change media to Fresh TeSR Media | Atvivin A 100ng/ml Wnt3a 25ng/ml | Atvivin 100ng/ml | Retinoic Acid 2uM SB431542 10uM Dorsomorphin 1uM B27 supplement 1% | Forskolin 10uM Dexametasone 10uM Alk5i II 10uM Nicotinamide 10mM B27 supplement 1% | Forskolin 10uM Dexametasone 10uM Alk5i II 10uM Nicotinamide 10mM B27 supplement 1% |
| | Red; Essential small molecules Blue; Additional small molecules | CHIR99021 3uM (Replacable to Wnt3a) | | | T3 1uM | dBu-cAMP 0.6uM T3 1uM |
| | Change media every day Matrigel coated well | Change media every day Matrigel coated well | Change media every day Matrigel coated well | Change media every other day Matrigel coated well | Change media every 2~3 days Matrigel coated well | Change media every 2~3 days Matrigel coated well |
| Base Midea | TeSR media | Custam TeSR media (w/o growth Factors, containing Vit C and GABA) | Custam TeSR media (w/o growth Factors, containing Vit C and GABA) | Custom TeSR media (w/o growth Factors, containing Vit C and GABA) | Custom TeSR media (w/o growth Factors, containing Vit C and GABA) | Custom TeSR media (w/o growth Factors, containing Vit C and GABA) |

Table S6

| | Treatment | C-peptide (ng/ml) | | C-peptide (%) | C-peptide (ng/ml) |
|----------|----------------|-------------------|--------------|------------------|-------------------|
| | | 3mM glucose | 20mM glucose | 20mM/3mM Glucose | 20mM KCl |
| Batch1 | iβL 1 | 0.231 | 0.231 | 100 | 0.587 |
| | iβL 2 | 0.203 | 0.207 | 102 | 0.811 |
| | iβL 3 | 0.169 | 0.158 | 93 | 0.891 |
| Batch2 | iβL GFP1 | 0.215 | 0.215 | 100 | |
| | iβL GFP2 | 0.205 | 0.227 | 111 | |
| | iβL GFP3 | 0.197 | 0.233 | 118 | |
| | iβL GFP4 | 0.205 | 0.223 | 109 | |
| | iβeta1 | 0.21 | 0.33 | 157 | |
| | iβeta2 | 0.205 | 0.517 | 252 | |
| | iβeta3 | 0.246 | 0.366 | 149 | |
| | iβeta4 | 0.207 | 0.484 | 234 | |
| Batch3 | iβL GFP1 | 0.173 | 0.173 | 100 | |
| | iβL GFP2 | 0.161 | 0.176 | 109 | |
| | iβL GFP3 | 0.164 | 0.173 | 105 | |
| | iβeta1 | 0.172 | 0.413 | 240 | |
| | iβeta2 | 0.175 | 0.307 | 175 | |
| | iβeta3 | 0.168 | 0.312 | 186 | |
| | human islets 1 | 1.455 | 5.27 | 362 | |
| | human islets 2 | 1.414 | 6.833 | 483 | |
| | human islets 3 | 1.298 | 5.921 | 456 | |
| | Batch4 | iβL GFP1 | 0.173 | 0.173 | 100 |
| iβL GFP2 | | 0.161 | 0.176 | 109 | |
| iβL GFP3 | | 0.164 | 0.173 | 105 | |
| iβeta1 | | 0.172 | 0.213 | 124 | |
| iβeta2 | | 0.175 | 0.207 | 118 | |
| iβeta3 | | 0.168 | 0.212 | 126 | |
| Batch5 | iβL GFP1 | 1.659 | 1.833 | 110 | 2.627 |
| | iβL GFP2 | 1.61 | 1.645 | 102 | 2.281 |
| | iβL GFP3 | 1.574 | 1.635 | 104 | 1.973 |
| | iβeta1 | 1.539 | 2.258 | 147 | 2.762 |
| | iβeta2 | 1.597 | 2.406 | 151 | 4.131 |
| | iβeta3 | 1.572 | 2.858 | 182 | 4.163 |
| Batch6 | iβL GFP1 | 1.184 | 0.677 | 57 | |
| | iβL GFP2 | 0.777 | 0.729 | 94 | |
| | iβL GFP3 | 0.867 | 0.52 | 60 | |
| | iβeta1 | 0.583 | 4.206 | 721 | |
| | iβeta2 | 0.573 | 3.336 | 582 | |
| | iβeta3 | 1.044 | 2.405 | 230 | |
| Batch7 | human islets 1 | 0.318 | 1.362 | 428 | |
| | human islets 2 | 0.836 | 2.168 | 259 | |
| | human islets 3 | 0.324 | 1.01 | 312 | |
| | human islets 4 | 1.182 | 1.44 | 122 | |
| | human islets 5 | 0.887 | 1.101 | 124 | |
| | human islets 6 | 1.302 | 1.064 | 82 | |

Figure S1, Related to Figure 1 and Table S1. Transcriptional differences between neonatal and adult islets (A) Heatmap of differentially expressed transcriptional factors involved in pancreatic lineage determination in islets from 2, 6, and 12 wk old C57BL/6J mice. 53 pancreatic lineage genes were selected based on published literature (Hrvatin *et al.*, 2014); the full gene list and expression data are provided in Table S1A. **(B-C)** Biological pathways enriched in neonatal (2 wk old) and adult (12 wk old) islets, determined by DAVID gene ontology (GO). **(D-E)** Relative expression of cell type-specific markers and *ERRγ* and the proliferative marker *Pdgfrβ* (n= 3) in FACS-sorted cell populations from mouse insulin promoter GFP (MIP-GFP) islets at 2 and 12 wks. *ERRγ* is induced during postnatal β cell development. **(F)** Immunoblot analysis for *ERRγ* and β-actin in neonate (2wk, n=6) and adult (9wk, n=3) islets. **(G)** X-gal staining showing enriched *ERRγ* expression in isolated islets (endocrine) but not pancreatic exocrine acini cells from 12 wk old *ERRγ lacZ* knock-in mice. Data represent the mean ±s.e.m. *p<0.05 Student's unpaired t-test.

Figure S2, Related to Figure 2. Characterization of β cell-specific *ERRγ* knockout mice (β*ERRγ*KO). **(A)** Relative expression of *ERRγ* in isolated islets and tissues from *ERRγ^{fl/fl}* (WT) and β*ERRγ*KO mice, measured by qPCR at 12 wks old (n=3). **(B)** Body weights of WT (n=9), β*ERRγ*KO (n=13) and WT(RIP-Cre) (n=12) mice at indicated developmental ages. **(C)** *Ad lib* fed blood glucose levels in male mice at indicated ages. **(D-E)** Intra-peritoneal glucose tolerance test (2g/kg; IP-GTT) of WT (n=6), β*ERRγ*KO (n=5), and WT (RIP-Cre) (n=5) mice fed a normal chow diet (NCD) in 15 and 40 wk old male mice. 12 wk old male WT (n=9) and Tamoxifen-induced β*ERRγ*KO (β*ERRγ*KO ER) (n=11) mice were given daily tamoxifen (Tam) injections (2mg/kg in corn oil, i.p.) for 7 days prior to **(F)** analysis of *ERRγ* expression in isolated islets or **(G)** IP-GTT at 16 wks. **(H-J)** Body weights, IP-GTT blood glucose, IP-GTT serum insulin level (ng/ml) of 16 wk old *ERRγ^{fl/fl}* (WT, n=9) and pancreatic-specific *ERRγ*KO (P*ERRγ*KO; *ERRγ^{fl/fl}* x PDX1-Cre, n=7) mice under NCD. **(K)** IP-GTT of 8 wk old in WT (n=7) and P*ERRγ*KO (n=6) after 4 wks high fat diet (HFD) after weaning. Data represent the mean ±s.e.m. *p<0.05 Student's unpaired t-test.

Figure S3, Related to Figure 2. HFD-fed β ERR γ KO islets are hypertrophic while ERR γ deletion disrupts insulin secretion in response to nutrients. (A) Immunostaining (insulin, green and glucagon, red), and (B) hematoxylin and eosin (H&E) staining of islets from 10 wk old ERR $\gamma^{f/f}$ (WT) and β ERR γ KO mice fed a normal chow diet (NCD) or after 6 wks on a high fat diet (HFD). (C) Insulin content of islets from 10 wk old WT and β ERR γ KO mice fed NCD or (D) 6 wks high fat diet (HFD). (E) Average area of islet in pancreas, (F) whole pancreas insulin content (ng/mg protein from whole pancreas) and (G) frequency distribution of islet sizes were measured from 10 wk old WT and β ERR γ KO mice fed 4-6 wks HFD after weaning. (WT, n=5-7; β ERR γ KO, n=5-7). Mice were started on HFD at the age of 4 wks. *Ex vivo* insulin secretion from (H) WT and β ERR γ KO or (I) WT and pancreatic-specific ERR γ KO (*PERR γ KO*) islets in response to nutrients (glucose, leucine and glutamine) and KCl. Islets were isolated from 10 wk old male mice. (J) Relative ERR γ expression, (K) glucose-stimulated (20mM) or KCl-stimulated (20mM) insulin secretion assay (L) cellular ATP levels, and (M) cellular bioenergetics in rat INS-1 cells at 72 hours after transfection with scrambled (Control) or ERR γ -targeted siRNA. Data represent the mean \pm s.e.m. *p<0.05 Student's unpaired t-test.

Figure S4, Related to Figure 3 and Table S1. ERR γ directly regulates postnatal islet maturation. (A) Schematic of genomic analyses of ERR γ -deleted β cells. Transcriptional changes between islets from ERR $\gamma^{f/f}$ (WT, n=3) and β ERR γ KO (n=3) mice were compared to the transcriptional changes between ERR $\gamma^{f/f}$ islets after adenoviral EGFP or Cre infection (n=10). Islets were isolated from 12 wk old male mice. (B) ERR/NR responsive elements identified in 140 down- and 149 up-regulated genes in β ERR γ KO islets. (C) ChIP assay for indicated genes in mouse insulinoma MIN-6 cell line. (D) Altered gene expression in ERR γ KO islets. Heatmap of 471 hierarchally clustered genes whose expression changed in β ERR γ KO islets compared to Control islets (ERR $\gamma^{f/f}$) are compared to postnatal developmental transcriptomic changes in WT islets at indicated ages. Heatmap values were shown as relative expression (Row Z-score). Full gene list with expression data are provided in Table S1C. Data represent the mean \pm s.e.m. *p<0.05 Student's unpaired t-test.

Figure S5, Related to Figure 4. Functional characterization of iPSC-derived β -like cells.

(A) Expression profiling of differentiating human iPSCs. Relative expression of the pluripotent marker (*NANOG*), endoderm marker (*Sox17*), pre-pancreatic foregut endoderm marker (*Hnf1 β*), pancreatic progenitor marker (*Pdx1*), and endocrine/ β -cell markers (Insulin, *Mafa*, *Nkx6-1*, *NeuroD1*, *Gck*, *Vamp2*, *Gcg*, *Sst*) in iPSCs during differentiation into β -like cells (i β L). (B) Human insulin reporter-driven (hIns) GFP expression (top panels) and phase contrast image (bottom panels) of day 30 i β L cells. (C) Human Pdx1 reporter-driven GFP expression (top panels) and phase contrast image (bottom panels) of day 23 i β L cells. (D) Percentage of i β L cells expressing hIns-driven GFP, as measured by FACS (n=8). (E) Representative FACS analyses of insulin (GFP) and glucagon expression in iPSCs and i β L cells. (F) EM analyses of i β L cells (day 22) and mouse primary β cells (arrows indicate representative mitochondria and insulin granules). (G) Co-expression of Insulin (GFP reporter) and *Nkx6-1* or *MafA* in iPSCs and i β L cells, as measured by FACS. IgG is shown as a negative control. (H) Glucose and potassium-stimulated c-peptide secretion from i β L cells. (I) Relative *ERR γ* expression in human islets, β -like cells with adenoviral EGFP expression (i β L^{GFP} cells) and β -like cells with adenoviral *ERR γ* expression (i β eta cells). (J) 20mM KCl-stimulated human c-peptide secretion from i β L^{GFP} and i β eta cells. Data were shown by % increased c-peptide secretion compared to basal (glucose 3mM, KCl 3.6mM) condition. (K) *Nkx6-1* and *MafA* expression in undifferentiated iPSCs, i β L and i β eta (*ERR γ* -expressing) cells. *ERR γ* overexpression does not enhance β cell marker expression. Data represent the mean \pm s.e.m.

Figure S6, Related to Figure 6. Pathways down-regulated in i β eta cells and schematic of cell transplantation experiments. (A) Functional annotation of down-regulated gene categories in i β eta cells, identified by Gene Ontology (GO). Heatmap of expression changes in selected genes involved in cell cycle. (B) Schematic of cell transplantation experiments. Type1 diabetic NOD-SCID mice were prepared by high-

dose (180mg/kg) STZ i.p. injection 7-10 days before transplantation. Day 22-30 iPSC-derived β -like cells were infected with adenoviral *ERR γ* (Ad-ERR γ) or control (Ad-GFP) and 10 million cells/mice were transplanted into kidney capsules of STZ-treated NOD-SCID mice within 5 days after virus infection. (C) *Ad lib*-fed blood glucose levels of individual mice described in Figure 6B.

Figure S7, Related to Figure 6. Kidney immunohistochemistry in transplanted mice.

Representative immunohistochemistry (IHC) staining and histology of human islets, i β eta cells and Mock grafts from kidney capsules of transplanted mice that were harvested 2 months post-transplant. Immunofluorescence of Insulin (Green), Glucagon (Red), Somatostatin (Red), nuclear DAPI (blue) staining and Hematoxylin & Eosin (H&E) staining as well as whole kidney images are provided.

Hrvatin, S., O'Donnell, C.W., Deng, F., Millman, J.R., Pagliuca, F.W., Diiorio, P., Rezania, A., Gifford, D.K., and Melton, D.A. (2014). Differentiated human stem cells resemble fetal, not adult, beta cells. *Proceedings of the National Academy of Sciences of the United States of America*.

Table S1, Related to Figure 1, 3 and Figure S1, S3. List showing comparison of gene expression in 2wk and 12wk islets. (A) Gene list for pancreatic lineage-specific gene expression in neonatal and adult islets related to Figure 1B and 1C. **(B)** Gene list for glucose metabolism, mitochondria metabolic genes include ATP Biosynthesis/ETC/OxPhos, Exocytosis and cell proliferation-specific gene expression related to Figure 1B and 1C. **(C)** Gene list for ERR γ regulated gene expression related to Figure 3D, 3F and 3G. Log₂ Fold change in expression between samples is compared. “Not Sig” indicates no significant change in expression between the samples and “NO TEST” indicates no expression in at least one of the samples being compared.

Table S2, Related to Figure 4. Gene List of representative up-regulated and down-regulated pathways in *i β eta* cells. Log₂ Fold change in expression between samples is compared. “Not Sig” indicates no significant change in expression between the samples and “NO TEST” indicates no expression in at least one of the samples being compared.

Table S3, Related to Figure, 4, 5, 6 and Figure S5, S6, S7. Additional information regarding human islets

Table S4, Related to Figure 1, 2, 3, 4, 5 and Figure S1, S2, S3, S4, S5. Primer information Primer sequence information for qPCR, ChIP and Genotyping

Table S5, Related to Figure 4 Stepwise differentiation protocol and small molecule information for insulin-producing cells. Small molecule information used for optimizing the β cell differentiation protocol. Simple strategy for the differentiation is also provided. Wnt3a can be replaced by CHIR99021. Addition of T3 and dBu-cAMP from 12 days after initiation of differentiation, increases the efficiency of β cell lineage specification.

Table S6, Related to Figure 4. Raw data for in vitro c-peptide secretion assay. Static glucose-stimulated human c-peptide secretion (ng/ml) by i β L, i β LGFP, i β eta and human islets. Details of experimental information are provided in Experimental Procedures.

ON-LINE SUPPLEMENTAL METHODS

INS-1 Cell culture, transfection and insulin secretion assay

INS-1 cells were cultured at 37°C in 5% CO₂ in air in RPMI-1640 (Sigma Aldrich) supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) Antibiotic-Antimycotic (Gibco) 10 mM HEPES, 2 mM glutamax, 1 mM sodium pyruvate, and 50 μM β-mercaptoethanol (RPMI for INS-1 medium). INS-1 cells were transfected with Lipofectamine2000 containing Plus Reagent (Invitrogen). INS-1 cells were transfected with ERRγ siRNA (Qiagen) or negative control scramble siRNA (Qiagen) for 72 hr. Insulin secretion was measured in pre-incubated cells (37°C for 30 min in KRBH with 3 mM glucose, as described in insulin secretion assays for primary islets) after a 30 min glucose challenge (KRBH buffer with 3 mM or 20 mM glucose) using a Rat/mouse Insulin ELISA kit (Millipore).

Histology (H&E staining, Immunohistochemistry and LacZ staining)

H&E staining was performed by Pacific Pathology (San Diego). Immunostaining was visualized by ZEISS confocal microscopy analysis or fluorescence microscopy analysis using the following antibodies on frozen or paraffin sections of pancreas and human islets or *β* cells in the kidney capsule and 4% PFA-fixed cells: Insulin (1/100, Abcam ab7842), glucagon (1/100, Abcam ab10988), somatostatin (1/100, Abcam ab103790). DAPI-containing mounting media (VECTASHIELD mounting medium for fluorescence) was used for nuclear staining. Whole pancreases from ERRγ knock-in mice (Alaynick et al., 2007) were fixed with paraformaldehyde and glutaraldehyde, and frozen sections

stained by X-gal.

Electron microscopy

Pancreatic isolated islets or hiPSC, hiPSC-derived iβL, iβL^{GFP} and *iβeta* cells on Acryl plate were fixed in 0.15M cacodylate buffer (pH 7.4) containing 2% paraformaldehyde and 2.5% glutaraldehyde with 2mM calcium chloride at 37°C for 5 min. Subsequently, EM analysis were performed in Biophotonics Core Facility at Salk institute.

Microarray Analyses

Total RNA was extracted from Ad-GFP or Ad-Cre infected islets using Trizol reagent (Invitrogen) and its quality determined by Agilent 2100 Bioanalyzer. 500 ng of RNA was reverse transcribed into cRNA and biotin-UTP labeled using the Illumina TotalPrep RNA Amplification Kit (Ambion). cRNA was quantified using an Agilent Bioanalyzer 2100 and hybridized to the Illumina mouseRefseq-8v2 Expression BeadChip using standard protocols (Illumina). Image data was converted into unnormalized Sample Probe Profiles using Illumina GenomeStudio. Data were analyzed by GeneSpring GX software. Briefly, per-chip normalizations were set to the 75th percentile, and per-gene normalizations to the median and specific samples. Genes assigned as absent were eliminated from the dataset and genes with an expression difference of 2-fold more than WT were selected.

Combination analyses by GO, pathway analyses and cluster analyses were performed using mainly DAVID software (Huang *et al.*, 2009a; Huang *et al.*, 2009b). The microarray data is deposited in the NCBI Gene Expression Omnibus and accessible through GEO Series accession number GSE56080.

Quantitative RT-PCR analysis

Total RNA was extracted using TRIzol reagent (Invitrogen) and RNeasy KIT (Qiagen). Reverse transcription was performed with a SuperScript III First-Strand Synthesis System kit (Invitrogen) or PrimeScript RT reagent kit (TAKARA). Real time quantitative RT-PCR (qPCR) was performed using SYBR Green (Bio-Rad). PCR analyses were carried out using the oligonucleotide primers listed in Table S4.

RNA-Seq library generation

Total RNA was isolated from cell pellets treated with RNAlater using the RNA mini kit (Qiagen) and treated with DNaseI (Qiagen) for 30 min at room temperature. Sequencing libraries were prepared from 100-500ng total RNA using the TruSeq RNA Sample Preparation Kit v2 (Illumina) according to the manufacturer's protocol. Briefly, mRNA was purified, fragmented, and used for first- and second-strand cDNA synthesis followed by adenylation of 3' ends. Samples were ligated to unique adapters and PCR amplified. Libraries were then validated using the 2100 BioAnalyzer (Agilent), normalized and pooled for sequencing.

High-throughput sequencing and analysis

RNA-Seq libraries prepared from 2-3 biological replicates for each experimental condition were sequenced on the Illumina HiSeq 2500 using bar-coded multiplexing and a 100bp read length. Image analysis and base calling were performed with Illumina CASAVA-1.8.2. This yielded a median of 29.9M usable reads per sample. Short

read sequences were mapped to a UCSC mm9 reference sequence using the RNA-Seq aligner STAR (Dobin *et al.*, 2013). Known splice junctions from mm9 were supplied to the aligner and *de novo* junction discovery was also permitted. Differential gene expression analysis, statistical testing and annotation were performed using Cuffdiff 2 (Trapnell *et al.*, 2013). Transcript expression was calculated as gene-level relative abundance in fragments per kilobase of exon model per million (fpkm) mapped fragments and employed correction for transcript abundance bias (Roberts *et al.*, 2011). RNA-Seq results for genes of interest were also explored visually using the UCSC Genome Browser. Heatmaps were generated by R-Script with heatmap.2 (gplot) software or Cluster with Javtree view software. Scale of heatmaps was determined by Z-score (Figure 1B, 1C, 3F, S1A and S4D) or fold change with log scale (Figure 3G, 4G and S6A). Motif analyses were performed using HOMER (Heinz *et al.*, 2010). Detailed methods for HOMER are freely available at <http://homer.salk.edu/homer/>. Briefly, the program searches against the target and background sequences for enrichment of known motifs, returning motifs enriched with a p-value less than 0.05. In this study, the promoter regions, defined as 1kB upstream from the transcription start site, of genes dysregulated in ERRg KO islets were interrogated for enriched motifs of 8-16 bp using HOMER motif analysis. This analysis revealed the ERR response element (ERREs) shown in Figure S4B as the 5th most enriched motif in the proximal 1kb promoter region of 140 down- and 149 up-regulated genes ($p=1e-15$). Other variations of the ERRE came up ranked 7th, 9th, and 10th.

RNA-Seq data can be accessed on the NCBI Sequence Read Archive under the

accessions SRP048600 and SRP048605.

Tamoxifen-inducible mouse experiments

Glucose tolerance tests were performed before (at 12 wks of age) and 3 wks after treatment (at 16 wks of age) in tamoxifen-inducible β cell-specific ERR γ -knockout mice. Male mice were given daily injections of tamoxifen (2mg/kg in corn oil, i.p.) for 7 days.

References for Online Methods

- Dobin, A. *et al.* STAR:ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21, (2013)
- Heinz S, Benner C, Spann N, Bertolino E *et al.* Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities. *Mol Cell* 2010 May 28;38(4):576-589.
- Huang, D. W., Sherman, B. T. & Lempick, R.A. Systemic and integrative analysis of large gene list using DAVID bioinformatics resources. *Nature protocols* **4**, 44-57, (2009)
- Huang, D. W., Sherman, B. T. & Lempick, R.A. Bioinformatics enriched tools: paths toward the comprehends functional analysis of large gene lists. *Nucleic acids research* **37**, 1-13, (2009)
- Roberts, A., Pimental, H., Trapnell, C. & Pachter, L. Identification of novel transcripts in annotated genomes using RNA-seq. *Bioinformatics* **27**, 2325-2329, (2011)
- Trapnell, C. *et al.* Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nature biotechnology* **31**, 46-53, (2013)